Digitalni repozitorij raziskovalnih organizacij Slovenije

Izpis gradiva
A+ | A- | Pomoč | SLO | ENG

Naslov:Art v 1 IgE epitopes of patients and humanized mice are conformational
Avtorji:ID Zabel, Maja (Avtor)
ID Weber, Milena (Avtor)
ID Kratzer, Bernhard (Avtor)
ID Köhler, Cordula (Avtor)
ID Jahn-Schmid, Beatrice (Avtor)
ID Gadermaier, Gabriele (Avtor)
ID Gattinger, Pia (Avtor)
ID Bidovec, Urška, Klinika Golnik (Avtor)
ID Korošec, Peter, Klinika Golnik (Avtor)
ID Smole, Ursula (Avtor)
ID Valenta, Rudolf (Avtor)
ID Pickl, Winfried F. (Avtor)
Datoteke:URL URL - Izvorni URL, za dostop obiščite https://www.jacionline.org/action/showPdf?pii=S0091-6749%2822%2900701-1
 
Jezik:Angleški jezik
Tipologija:1.01 - Izvirni znanstveni članek
Organizacija:Logo UKPBAG - Univerzitetna klinika za pljučne bolezni in alergijo Golnik
Povzetek:Background: Worldwide, pollen of the weed mugwort (Artemisia vulgaris) is a major cause of severe respiratory allergy, with its major allergen, Art v 1, being the key pathogenic molecule for millions of patients. Humanized mice transgenic for a human T-cell receptor specific for the major Art v 1 T-cell epitope and the corresponding HLA have been made. Objective: We sought to characterize IgE epitopes of Art v 1–sensitized patients and humanized mice for molecular immunotherapy of mugwort allergy. Methods: Four overlapping peptides incorporating surface-exposed amino acids representing the full-length Art v 1 sequence were synthesized and used to search for IgE reactivity to sequential epitopes. For indirect mapping, peptide-specific rabbit antibodies were raised to block IgE against surface-exposed epitopes on folded Art v 1. IgE reactivity and basophil activation studies were performed in clinically defined mugwort-allergic patients. Secondary structure of recombinant (r) Art v 1 and peptides was determined by circular dichroism spectroscopy. Results: Mugwort-allergic patients and humanized mice sensitized by allergen inhalation showed IgE reactivity and/or basophil activation mainly to folded, complete Art v 1 but not to unfolded, sequential peptide epitopes. Blocking of allergic patients’ IgE with peptide-specific rabbit antisera identified a hitherto unknown major conformational IgE binding site in the C-terminal Art v 1 domain. Conclusions: Identification of the new major conformational IgE binding site on Art v 1, which can be blocked with IgG raised against non-IgE reactive Art v 1 peptides, is an important basis for the development of a hypoallergenic peptide vaccine for mugwort allergy.
Ključne besede:mugwort pollen allergy, IgE epitope, allergen-specific immunotherapy
Datum sprejetja članka:21.04.2022
Datum objave:20.06.2022
Leto izida:2022
Št. strani:str. 1-11
Številčenje:Vol. 150, iss.
PID:20.500.12556/DiRROS-15408 Novo okno
UDK:616-097
ISSN pri članku:1097-6825
DOI:10.1016/j.jaci.2022.04.031 Novo okno
COBISS.SI-ID:116269571 Novo okno
Opomba:Soavtorja iz Slovenije: Urška BIdovec-Srojković, Peter Korošec; Nasl. z nasl. zaslona; Opis vira z dne 22. 7. 2022;
Datum objave v DiRROS:31.08.2022
Število ogledov:944
Število prenosov:394
Metapodatki:XML DC-XML DC-RDF
:
Kopiraj citat
  
Objavi na:Bookmark and Share


Postavite miškin kazalec na naslov za izpis povzetka. Klik na naslov izpiše podrobnosti ali sproži prenos.

Gradivo je del revije

Naslov:The journal of allergy and clinical immunology
Skrajšan naslov:J. allergy clin. immunol.
Založnik:Elsevier
ISSN:1097-6825
COBISS.SI-ID:3614228 Novo okno

Gradivo je financirano iz projekta

Financer:FWF - Austrian Science Fund
Program financ.:Doktoratskollegs (DKs)
Številka projekta:W 1248
Naslov:Molecular, cellular and clinical allergology, MCCA

Financer:FWF - Austrian Science Fund
Program financ.:Spezialforschungsbereiche (SFBs)
Številka projekta:F4609

Financer:Drugi - Drug financer ali več financerjev
Naslov:theDANUBE-ARC grant of the country of Lower Austria

Financer:Drugi - Drug financer ali več financerjev
Naslov:grant from WORG Pharmaceuticals

Sekundarni jezik

Jezik:Slovenski jezik
Ključne besede:alergija za pelod pelina, epitop IgE, specifična imunoterapija


Nazaj